Bernstein raises Zimmer Biomet stock price target to $105 on improving outlook

Published 08/08/2025, 14:16
Bernstein raises Zimmer Biomet stock price target to $105 on improving outlook

Investing.com - Bernstein SocGen Group raised its price target on Zimmer Biomet (NYSE:ZBH) to $105.00 from $100.00 on Friday, while maintaining a Market Perform rating on the medical device maker’s stock. The company, with a market capitalization of $19.47 billion, has seen its shares surge 8.62% over the past week.

The price target increase represents a 5% upward revision from the firm’s previous valuation, reflecting a higher price-to-earnings multiple of 12.0x compared to the previous 11.5x multiple. The stock currently trades at 22.18x earnings, with analyst targets ranging from $95 to $138.

Bernstein applied this multiple to its forward Q5-Q8 earnings per share estimate of $8.76, which was also revised upward from the previous estimate of $8.66.

The research firm noted that Zimmer Biomet’s "story is improving" based on current performance metrics and company guidance.

Bernstein indicated further potential upside exists if the company successfully executes "its plan for steep growth acceleration" expected in the second half of 2025.

In other recent news, Zimmer Biomet Holdings reported second-quarter earnings that surpassed analyst expectations. The company’s strong performance was attributed to its U.S. hip and knee portfolios, as well as its global S.E.T. business. In light of these results, Zimmer Biomet has raised its full-year earnings guidance. These developments reflect the company’s positive momentum in the medical device sector. The announcement of the earnings results comes as a significant update for investors. Zimmer Biomet’s financial performance and outlook adjustments are key points of interest in the current market environment. Investors and analysts will be closely monitoring how these changes impact the company’s future financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.